In this study, the seroprevalence of CMV-specific IgG antibodies was assessed in 13,761 individuals aged 0–97 years from South Transdanubia, Hungary. Overall 69.2% of the participants were found to be CMV IgG seropositive, a proportion comparable to the estimated prevalence of 66% in the WHO European region [
18], but lower than 84–86% reported by Varga et al. [
23,
24].
The seroprevalence increases with age, consistent with other international studies. Approximately 40% of the infections occurred within the first five years of life, and half of the estimated population were seropositive by 25 years. These findings indicate that the most infections occur in childhood and early adulthood, in agreement with previous reports [
2,
3]. The women seemed to be more affected in line with Varga et al. [
22,
23]. Perhaps the reason for this is that women are the primary caretakers of children whose bodily fluids are the main source of the infection [
2,
3]. Interestingly, we observed a slight decrease in the percentage of seropositivity between 2020 and 2023, but significance was only found in two age groups (21–25 and 51–55 years) and not associated with sexes. The cause of this phenomena is unknown, but two factors i) restrictions and containment measures during the SARS-CoV-2 pandemic and the ii) increased number of specimens in this time period could affected to the statistical results. Possible changes in CMV seroprevalence needs to be followed up in the future. Otherwise decreasing trend (∼4%) was also observed by Gorun et al. [
20] in Romania comparing two cohorts of pregnant women from 2008 to 2010 and 2015 to 2018.
There could be several reasons why our observed seropositivity is lower (69.2%) than 84–86% that observed by Varga et al. [
22,
23]: i) there was a higher proportion of samples from overrepresented older age groups in the Varga et al. study which may have increased their mean CMV IgG seroprevalence value comparing to ours. This may be confirmed by the fact that Mihály et al. [
24] found a lower (65.4%) seropositivity rate among pregnant women between age 18 and 46 years, ii) Varga et al. used samples collected between 1998 and 2007 which does not overlap with the sample collection period of our study; iii) our study only represents one region (South Transdanubia) of Hungary and we should notice the correspondence between CMV prevalence and socioeconomic status therefore prevalence can vary in differentially developed regions within one country.
A specific group of interest related to CMV is women of childbearing age. The women between 16 and 45 years showed a 61.2% seropositivity in our study which means 38.8% of these examined women are not protected against a primary CMV infection. The ratio of unprotected women of childbearing age are higher (44.8%) under 30 years. The high (65.2%) seroprevalence among children under 1 year mostly also represents the women in child-bearing age due to the presence of maternal CMV IgG antibodies. These results are in line with Mihály et al. [
24], who found a 65.4% seropositivity rate among pregnant women. Comparing with available studies from Europe, our results place between Germany (56.7%) and Poland (81.9%) [
17,
19].